KOD
Kodiak Sciences Inc.
NASDAQ · Healthcare · Biotechnology · US
$32.71
−0.43%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$32.92
From 52W high−29.57%
Volume1.60M
Market cap$2.06B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$32.92
From 52W high
−29.57%
Volume
1.60M
Market cap
$2.06B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.2x
P/E (TTM)
—
RSI (14)
27.3
MomentumView details →
1D Return
−0.43%
YTD Return
+13.77%
SummaryUpdated Jun 1, 2026
Kodiak Sciences Inc. (NASDAQ:KOD) is a clinical-stage biopharmaceutical company founded in 2009 and based in Palo Alto, California. Originally incorporated as Oligasis, LLC, the company changed its name to Kodiak Sciences in September 2015 and went public in October 2018. Kodiak focuses on developing novel therapeutics to treat retinal diseases, with its lead drug candidate currently in late-stage clinical trials for several sight-threatening conditions affecting millions of patients worldwide.
Similar companies
Latest newsMore news →
Kodiak Sciences Inc. reported a net loss of $65.6 million, or $1.05 per diluted share, for Q2 2026, compared to a net loss of $54.3 million, or $1.03 per diluted share, in Q2 2025.39d agoKodiak Sciences initiated a global phase III clinical trial of KSI-501 for diabetic macular edema, evaluating a dual IL-6 and VEGF inhibitor approach.40d ago